SCHEMBL4125733

SCHEMBL4125733

O=C(O)Cc1ccc(NC2=NC(=O)/C(=C\c3cc4ccccc4cc3OCc3ccccc3)S2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 3/20 0.50
PTPN1 P18031 5/20 0.40
CISD1 Q9NZ45 1/20 0.40
MEN1 O00255 6/20 0.39
KMT2A Q03164 6/20 0.39
POLB P06746 4/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TTR P02766 1/20 0.39
BLM P54132 1/20 0.39
PLA2G1B P04054 1/20 0.39
HTT P42858 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
IKBKB O14920 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125736 1.00 PTP4A3 (0.50) PTP4A3PTPN1CISD1MEN1KMT2A
SCHEMBL4131686 0.95 MEN1 (0.45) PTP4A3PTPN1CISD1MEN1KMT2A
SCHEMBL4131690 0.95 MEN1 (0.45) PTP4A3PTPN1CISD1MEN1KMT2A
SCHEMBL4133685 0.92 PTP4A3 (0.49) PTP4A3PTPN1CISD1MEN1KMT2A
SCHEMBL4133682 0.92 PTP4A3 (0.49) PTP4A3PTPN1CISD1MEN1KMT2A
SCHEMBL4128440 0.92 MEN1 (0.44) PTP4A3MEN1KMT2APOLBBLM
SCHEMBL4128445 0.92 MEN1 (0.44) PTP4A3MEN1KMT2APOLBBLM
SCHEMBL4137638 0.91 PTP4A3 (0.51) PTP4A3PTPN1CISD1POLBTDP1
SCHEMBL4137639 0.91 PTP4A3 (0.51) PTP4A3PTPN1CISD1POLBTDP1
SCHEMBL4127749 0.90 KMT2A (0.46) PTP4A3MEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTP4A3 26/4885PTPN1 7/4885CISD1 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.